HER2 targeted therapies for cancer and the gastrointestinal tract

Current Drug Targets

Volumn 10, Issue 6, 2009, Pages 537-542

  Al Dasooqi, Noor ^a,b   Gibson, Rachel ^a,b   Bowen, Joanne ^a,b   Keefe, Dorothy ^a,b,c  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b ROYAL ADELAIDE HOSPITAL   (Australia)

^c CANCER COUNCIL SOUTH AUSTRALIA   (Australia)

Author keywords

Gastrointestinal tract; HER2; Mucositis; Targeted anti cancer therapy; Toxicity

Indexed keywords

4 [1 (3 FLUOROBENZYL) 5 INDAZOLYLAMINO] 5 METHYLPYRROLO[2,1 F][1,2,4]TRIAZINE 6 CARBAMIC ACID 3 MORPHOLINOMETHYL ESTER; 4 [3 CHLORO 4 (2 PYRIDINYLMETHOXY)ANILINO] 3 CYANO 6 (4 DIMETHYLAMINOCROTONAMIDO) 7 ETHOXYQUINOLINE; CANERTINIB; CAPECITABINE; CARBOPLATIN; CYTOTOXIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; LAPATINIB; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 4D5; PACLITAXEL; PELITINIB; PERTUZUMAB; PROTEIN TYROSINE KINASE INHIBITOR; TAK 165; TRASTUZUMAB; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADVANCED CANCER; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CARCINOGENESIS; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; GENE OVEREXPRESSION; HEAD AND NECK CARCINOMA; HUMAN; LUNG NON SMALL CELL CANCER; METASTASIS; MUCOSA INFLAMMATION; NAUSEA; OVARY CANCER; PANCREAS CANCER; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; VOMITING;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; GASTROINTESTINAL TRACT; HUMANS; MUCOSITIS; NEOPLASMS; PROTEIN KINASE INHIBITORS; RECEPTOR, ERBB-2;

EID: 68349143101     PISSN: 13894501     EISSN: None     Source Type: Journal    
DOI: 10.2174/138945009788488440     Document Type: Review

References (65)

1. Keefe D, Schubert M, Elting L, Sonis S, Epstein J, Raber-Durlacher J, et al. Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer 2007; 109: 820-31.
2. Sonis S. The pathobiology of mucositis. Nat Rev Cancer 2004; 4: 277-84.
3. Blijlevens N and Sonis S. Palifermin (recombinant keratinocyte growth factor-1): a pleiotropic growth factor with multiple biological activities in preventing chemotherapy- and radiotherapy-induced mucositis. Ann Oncol 2006; 18: 817-26.
4. Yeoh A, Bowen J, Gibson R, and Keefe D. Nuclear Factor κB (NFκB) and Cyclooxygenase-2 (COX-2) expression in the irradiated colorectum is associated with subsequent histopathological changes. Int J Radiat Oncol Biol Phys 2005; 63: 1295-303.
5. Keefe D and Gibson R. Mucosal injury from targeted anticancer therapy. Support Care Cancer 2007; 15: 483-90.
6. Hussain S, Palmer D, Spooner D, and Rea D. Molecularly targeted therapeutics for breast cancer. BioDrugs 2007; 21: 215-24.
7. Zelnak A and O'Regan R. Targeting angiogenesis in advanced breast cancer. BioDrugs 2007; 21: 209-14.
8. Pickering L, Rudman S, Ross P, and Leslie M. Targeted therapy in colorectal carcinoma: more than a theory. Colorectal Dis 2008; 10: 209-18.
9. Willett C, Duda D, Czito B, Bendell J, Clark J, and Jain R. Targeted therapy in rectal cancer. Oncology (Williston Park) 2007; 21: 1055-65.
10. Besse B, Ropert S, and Soria J. Targeted therapies in lung cancer. Ann Oncol 2007; 18: 135-42.
11. Bianco R, Gelardi T, Damianco V, Ciardiello F, and Tortora G. Rational bases for the development of EGFR inhibitors for cancer treatmet. Int J Biochem Cell Biol 2007; 39: 1416-31.
12. Al-Dasooqi N, Bowen J, Gibson R, Sullivan T, Lees J, and Keefe D. Trastuzumab induces gastrointestinal side effects in HER2-overexpressing breast cancer patients. Invest New Drugs 2008; 27: 173-8.
13. Crone S, Negro A, Trumpp A, Giovannini M, and Lee K. Colonic epithelial expression of ErbB2 is required for postnatal maintenance of the enteric nervous system. Neuron 2003; 37: 29-40.
14. Price-Schiavi S, Andrechek E, Idris N, Li P, Rong M, Zhang J, et al. Expression, location and interactions of ErbB2 and its intramembrane ligand Muc4 (sialomucin complex) in rat mammary gland during pregnancy. J Cell Physiol 2005; 203: 44-53.
15. Badache A and Goncalves A. The ErbB2 Signalling Network as a target for Breast Cancer Therapy. J Mammary Gland Biol Neoplasia 2006; 11: 13-25.
16. Downward J, Yarden Y, Mayes E, Scarce G, Totty N, Stockwell P, et al. Close similarity of epidermal growth factor receptor and verb-B oncogene protein sequences. Nature 1984; 307: 521-7.
17. Sahin F, Yilmaz Z, Yagmurdur M, Atac F, Ozdemir B, Karakayali H, et al. Clinical findings and HER-2/neu gene amplification status of breast carcinoma patients. Pathol Oncol Res 2006; 12: 211-5.
18. Holbro T, Civenni G, and Hynes N. The ErbB receptors and their role in cancer progression. Exp Cell Res 2003; 284: 99-110.
19. Nagy P, Jenei A, Damjanovich S, Jovin T, and Szollosi J. Complexity of signal transduction mediated by ErbB2: clues to the potential of receptor-targeted cancer therapy. Pathol Oncol Res 1999; 5: 255-71.
20. Worthylake R, Opresko L, and Wiley H. ErbB-2 amplification inhibits down-regulation and induces constitutive activation of both erbB-2 and epidermal growth factor receptors. J Biol Chem 1999; 274: 8865-74.
21. Falcioni R, Antonini A, Nistico P, Di Stefano S, Crescenzi M, Natali P, et al. Alpha 6 beta 4 and alpha 6 beta 1 integrins associate with ErbB-2 in human carcinoma cell lines. Exp Cell Res 1997; 236: 76-85.
22. Petit A, Rak J, Hung M, Rockwell P, Goldstein N, Fendly B, et al. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol 1997; 151: 1523-30.
23. Spector N, Xia W, El-Hariry I, Yarden Y, and Bacus S. Small molecule HER-2 tyrosine kinase inhibitors. Breast Cancer Res 2007; 9: 205.
24. Imai K and Takaoka A. Comparing antibody and small-molecule therapies for cancer. Nat Rev Cancer 2006; 6(9): 714-27.
25. Morabito A, De Maio E, Di Maio M, Normanno N, and Perrone F. Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: current status and future directions. Oncologist 2006; 11(7): 753-64.
26. Becker JC, Muller-Tidow C, Serve H, Domschke W, and Pohle T. Role of receptor tyrosine kinases in gastric cancer: new targets for a selective therapy. World J Gastroenterol 2006; 12(21): 3297-305.
27. Baselga J. Clinical trials of Herceptin (Trastuzumab). Eur J Cancer 2001; 37: 18-24.
28. Cobleigh M, Vogel C, Tripathy D, Robert N, and al e. Multinational study of the efficacy and safety of the humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999; 17: 2639-48.
29. Plosker G and Keam S. Trastuzumab: a review of its use in the management of HER2-positive metastatic and early stage breast cancer. Drugs 2006; 66: 449-75.
30. Fountzilas G, Tsavdaridis D, Kalogera-Fountzila A, Christodoulou C, Timotheadou E, Kalofonos C, et al. Weekly paclitaxel as first-line chemotherapy and trastuzumab in patients with advanced breast cancer. A Hellenic Cooperative Oncology Group phase II study. Ann Oncol 2001; 12: 1545-51.
31. Bartsch R, Wenzel C, Altorjai G, Pluschnig U, Rudas M, Mader R, et al. Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer. J Clin Oncol 2007; 25: 3853-8.
32. Ruiz M, Salvador J, Bayo J, Lomas M, Moreno A, Valero M, et al. Phase-II study of weekly schedule of trastuzumab, paclitaxel, and carboplatin followed by a week off every 28 days for HER2+ metastatic breast cancer. Cancer Chemother Pharmacol 2008; 62: 1085-90.
33. Moy B and Goss P. Lapatinib-associated toxicity and practical management recommendations. Oncologist 2007; 12: 756-65.
34. Burris H. Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor lapatinib. Oncologist 2004; 9: 10-15.
35. Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006; 355(26): 2733-43.
36. Fabian M, Biggs W, Treiber D, Atteridge C, Aziomioara M, Benedetti M, et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol 2005; 23: 329-36.
37. Sonis S. A biological approach to mucositis. J Support Oncol 2004; 2: 21-32.
38. Bowen J, Gibson R, Tsykin A, Stringer A, Logan R, and Keefe D. Gene expression analysis of multiple gastrointestinal regions reveals activation of common cell regulatory pathways following cytotoxic chemotherapy. Int J Cancer 2007; 121: 1847-56.
39. Sonis S, Scherer J, Phelan S, Lucey C, Barron J, O'Donnell K, et al. The gene expression sequence of radiated mucosa in an animal mucositis model. Cell Prolif 2002; 35: s92-s102.
40. Gullick W, Berger M, Bennett P, Rothbard J, and Waterfield M. Expression of the c-erbB2 protein in normal and transformed cells. Int J Cancer 1987; 40: 246-54.
41. Carraway K, Perez A, Idris N, Jepson S, Arango M, Komatsu M, et al. Muc4/sialomucin complex, the intramembrane ErbB2 ligand, in cancer and epithelia: to protect and to survive. Prog Nucleic Acid Res Mol Biol 2002; 71: 149-85.
42. Ramsauer V, Carraway C, Salas P, and Carraway K. Muc4/ Sialomucin complex, the intramembrane ErbB2 ligand, translocates ErbB2 to the apical surface in polarized epithelial cells. J Biol Chem 2003; 278: 30142-7.
43. Kanehisa M, Araki M, Goto S, Hattori M, Hirakawa M, Itoh M, et al. KEGG for linking genomes to life and the environment. Nucleic Acids Res 2008; 36: D480-D484.
44. Kanehisa M and Goto S. KEGG: Kyoto Encyclopedia of genes and genomes. Nucleic Acids Res 2000; 28: 27-30.
45. Kanehisa M, Goto S, Hattori M, Aoki-Kinoshita K, Itoh M, Kawashima S, et al. From genomics to chemical genomics: new developments in KEGG. Nucleic Acids Res 2006; 34: D354-7.
46. Gibson R and Stringer A. Chemotherapy-induced diarrhoea. Current Opin Support Palliat Care 2009; 3(1): 31-5.
47. Stringer A, Gibson R, Bowen J, and Keefe D. Chemotherapy-induced changes to microflora: Evidence and implications of change. Curr Drug Metab 2009; 10: 79-83.
48. Stringer A, Gibson R, Logan R, Bowen J, Yeoh A, and Keefe D. Gastrointestinal microflora and mucins play a role in the development of 5-Fluorouracil-induced gastrointestinal mucositis in rats. Exp Biol Med 2009; 234: 430-41.
49. Stringer A, Gibson R, Bowen J, Ashton K, Logan R, Al-Dasooqi N, et al. Irinotecan-induced mucositis manifesting as diarrhoea corresponds with an amended intestinal flora and mucin profile. Int J Exp Pathol 2009; (Epub ahead of print).
50. Stringer A, Gibson R, Logan R, Bowen J, Yeoh A, and Keefe D. Faecal microflora and β-glucuronidase expression are altered in an irinotecan-induced diarrhoea model in rats. Cancer Biol Ther 2008; 7: 1919-25.
51. Chow J, Carlstrom K, and Barrett K. Growth hormone reduces chloride secretion in human colonic epithelial cells via EGF receptor and the extracellular regulated kinase. Gastroenterology 2003; 125: 1114-24.
52. Piazzi G, Paterini P, Ceccarelli C, Pantaleo M, and Biasco G. Molecular determination of epidermal growth factor receptor in normal and neoplastic colorectal mucosa. Br J Cancer 2006; 95: 1525-8.
53. Dise R, Frey M, Whitehead R, and Polk D. Epidermal growth factor stimulates Rac activation through Src and phosphatidylinositol 3-kinase to promote colonic epithelial cell migration. Am J Physiol Gastrointest Liver Physiol 2008; 294: 276-85.
54. Piccart-Gebhart M, Procter M, and Leyland-Jones B. Trastuzumab after adjunctive chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353: 1659-72.
55. Pegram M, Konecny G, O'Callaghan C, Beryt M, Pietras R, and Slamon D. Rational combinations of Trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl Cancer Inst 2004; 96: 739-49.
56. Romond E, Perez E, Bryant J, Suman V, Geyer C, Davidson N, et al. Trastuzumab plus adjunctive chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353: 1673-84.
57. Kataoka A, Ishida M, Murakami S, and Ohno S. Sensitization of chemotherapy by anti-HER. Breast Cancer 2004; 11: 105-15.
58. Madson J and Hanson L. Multiple mechanisms of ErbB2 action after ultraviolet irradiation of the skin. Mol Carcinog 2007; 46: 624-8.
59. Mihaljevic A, Buchler P, Harder J, Hofheinz R, Gregor M, Kanzler S, et al. A prospective, non-randomized phase-II trial of Trastuzumab and Capecitabine in patients with HER2 expressing advanced pancreatic cancer. BMC Surg 2009; 9: 1.
60. Albanell J, Montagut C, Jones E, Pronk L, Mellado B, Beech J, et al. A phase I study of the safety and pharmacokinetics of the combination of pertuzumab (rhuMab 2C4) and capecitabine in patients with advanced solid tumors. Clin Cancer Res 2008; 14: 2726-31.
61. Attard G, Kitzen J, Blagden S, Fong P, Pronk L, Zhi J, et al. A phase Ib study of pertuzumab, a recombinant humanised antibody to HER2, and docetaxel in patients with advanced solid tumours. Br J Cancer 2007; 97: 1338-43.
62. Walshe J, Denduluri N, Berman A, Rosing D, and Swain S. A phase II trial with trastuzumab and pertuzumab in patients with HER2-overexpressed locally advanced and metastatic breast cancer. Clin Breast Cancer 2006; 6: 535-9.
63. Harrington K, El-Hariry I, Holford C, Lusinchi A, Nutting C, Rosine D, et al. Phase I study of lapatinib in combination with chemoradiation in patients with locally advanced squamous cell carcinoma of the head and neck. J Clin Oncol 2009; 27: 1100-7.
64. Jänne P, von Pawel J, Cohen R, Crino L, Butts C, Olson S, et al. Multicenter, randomized, phase II trial of CI-1033, an irreversible pan-ERBB inhibitor, for previously treated advanced non small-cell lung cancer. J Clin Oncol 2007; 25: 3936-44.
65. Campos S, Hamid O, Seiden M, Oza A, Plante M, Potkul R, et al. Multicenter, randomized phase II trial of oral CI-1033 for previously treated advanced ovarian cancer. J Clin Oncol 2005; 23: 5597-604.